Direxion Daily MSCI South Korea Bull 3X Shares ETF (KORU)
Direxion Daily MSCI South Korea Bull 3x Shares (NYSEARCA:KORU) Sees Significant Increase in Short Interest
Direxion Daily MSCI South Korea Bull 3x Shares (NYSEARCA:KORU - Get Free Report) was the target of a large increase in short interest in February. As of February 27th, there was short interest totaling 150,347 shares, an increase of 123.4% from the February 12th total of 67,302 shares. Currently, 11.3% of the company's stock are
3 Reasons This South Korea ETF Is up Over 100% YTD
Volatility continues to rain down on the markets, but there are some shining stars in the bullish leveraged ETF arena. One particular standout is the Direxion Daily South Korea Bull 3X Shares (KORU), which is up over 100% for the year and nearly 400% within the past six months.
A 1,012% One Year Return Could Not Protect KORU From Its Own Structure
A highly-leveraged ETF, Direxion Daily MSCI South Korea Bull 3X ETF ( NYSEARCA:KORU ) dropped 26% in the past week, pulling back from $602.99 to $446.91, even as the fund sits on a staggering 135% gain year-to-date.
Looking to Leverage Country ETFs? Here's 2 to Ponder
Emerging market (EM) equities continue to be the benefactors of a weaker dollar, giving traders plenty of profitable opportunities in EM. Single-country ETFs are in play, with two traders may want to ponder: the Direxion Daily South Korea Bull 3X Shares (KORU) and the Direxion Daily MSCI Mexico Bull 3X Shares (MEXX).
KORU: Navigating 2025 Volaility
The Direxion Daily MSCI South Korea Bull 3X Shares aims for 300% daily returns of the MSCI Korea 25/50 Index but is risky as a long term hold. This ETF can yield significant gains during bull runs but can also incur substantial losses during downturns, as seen in Q4 2024. South Korea's stock market has rebounded from December lows but faces economic and political uncertainties, making short-term pullbacks likely.
KORU Medical Systems Has A Long Runway
KORU Medical Systems' stock has surged 60% since November, driven by the success of its FREEDOM System for subcutaneous immunoglobulin delivery. The SCIg market is growing rapidly, with KORU outperforming competitors by capturing market share and benefiting from trends like prefilled syringes. Strong international growth, new therapies, and product innovations are key drivers, with significant revenue from recurring patients and promising future launches.
Impressive Turnaround At KORU Medical
KORU Medical Systems is poised for growth with solid revenue increases, multiple growth drivers, and a chance to reach cash flow breakeven in Q4. The FREEDOM system, designed for at-home drug delivery, offers recurring revenue from consumables and is gaining market share in the SCIg market. International expansion and novel therapies present significant growth opportunities, with international revenue growing 46% and novel therapies progressing to Phase 3 trials.
South Korea Could Offer Traders Opportunities in EM
Opportunities in China might be the first place to look for emerging market (EM) trade opportunities. But South Korea shouldn't be overlooked.
